Supplemental_NNP financial_JJ information_NN Summary_NNP of_IN differences_NNS between_IN UK_NNP and_CC US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS unaudited_JJ The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT adjustments_NNS to_TO the_DT groups_NNS net_JJ income_NN and_CC shareholders_NNS equity_NN of_IN applying_VBG the_DT significant_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
These_DT are_VBP summarised_VBN in_IN the_DT tabular_JJ reconciliation_NN statements_NNS set_VBN out_RP below_IN and_CC ,_, subject_JJ to_TO any_DT matters_NNS that_WDT may_MD require_VB adjustment_NN ,_, will_MD be_VB included_VBN in_IN the_DT groups_NNS US_NNP Annual_JJ Report_NNP on_IN Form_NN 20-F_NN which_WDT provides_VBZ further_JJ details_NNS ._.
Reconciliation_NNP of_IN consolidated_JJ net_JJ income_NN 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_NNP Notes_NNP m_NN m_NN profit_NN attributable_JJ to_TO shareholders_NNS reported_VBN under_IN UK_NNP GAAP_NNP 178.7_CD 210.7_CD US_NNP GAAP_NNP adjustments_NNS :_: Business_NNP combinations_NNS i_FW 113.8_CD 107.7_CD Goodwill_NNP ,_, intangible_JJ and_CC other_JJ assets_NNS 42.2_CD 107.7_CD Effect_NN of_IN SFAS_NNP 142_CD Goodwill_NNP and_CC other_JJ intangibles_NNS 36.6_CD Purchase_NN of_IN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS 108.2_CD Accounting_NN for_IN investment_NN in_IN NMP_NNP goodwill_NN amortisation_NN ii_FW 3.6_CD Investment_NN in_IN Nycomed_NNP Pharma_NNP i_FW 0.3_CD Disposal_NNP of_IN Nycomed_NNP Pharma_NNP iii_FW 1.2_CD 10.4_CD Derivative_JJ hedging_VBG iv_NN 66.4_CD 5.6_CD Pension_NN and_CC post_NN retirement_NN costs_NNS v_VBP 4.4_CD 0.9_CD Transfer_NNP of_IN assets_NNS from_IN former_JJ pension_NN plans_NNS vi_FW 1.0_CD 6.0_CD Revenue_NN recognition_NN vii_FW 1.2_CD 2.9_CD Deferred_JJ taxation_NN application_NN of_IN full_JJ liability_NN method_NN viii_NN 5.9_CD 5.6_CD Other_JJ ix_NN 0.3_CD 10.0_CD Tax_NNP effect_NN of_IN US_NNP GAAP_NNP adjustments_NNS viii_FW 29.7_CD 20.5_CD Minority_NNP interest_NN xi_NN 1.1_CD 10.0_CD Total_JJ US_NNP GAAP_NNP adjustments_NNS 18.2_CD 86.3_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 160.5_CD 124.4_CD Basic_JJ net_JJ income_NN per_IN share_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 23.4_CD p_NN 19.6_CD p_VBP Diluted_JJ net_JJ income_NN per_IN share_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 23.3_CD p_NN 19.5_CD p_NN Reconciliation_NNP of_IN shareholders_NNS equity_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_NNP Note_NN m_NN m_NN Equity_NNP shareholders_NNS funds_NNS reported_VBN under_IN UK_NNP GAAP_NNP 1,172.0_CD 596.3_CD US_NNP GAAP_NNP adjustments_NNS :_: Business_NNP combinations_NNS i_FW 1,067.5_CD 1,093.7_CD Goodwill_NNP ,_, intangible_JJ and_CC other_JJ assets_NNS 1,039.5_CD 1,093.7_CD Effect_NN of_IN SFAS_NNP 142_CD Goodwill_NNP and_CC other_JJ intangibles_NNS 36.6_CD Purchase_NN of_IN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS 8.6_CD Accounting_NN for_IN investment_NN in_IN NMP_NNP ii_FW 41.7_CD 41.7_CD Investment_NN in_IN Nycomed_NNP Pharma_NNP i_FW ,_, iii_FW 1.5_CD Derivative_JJ hedging_VBG iv_NN 32.9_CD 12.8_CD Pension_NN and_CC post_NN retirement_NN costs_NNS v_VBP 73.5_CD 26.1_CD Transfer_NNP of_IN assets_NNS from_IN former_JJ pension_NN plans_NNS vi_FW 5.0_CD 6.0_CD Revenue_NN recognition_NN vii_FW 3.9_CD 2.9_CD Deferred_JJ taxation_NN application_NN of_IN full_JJ liability_NN method_NN viii_FW 27.6_CD 28.7_CD Other_JJ ix_NN 22.3_CD 23.7_CD Ordinary_NNP dividend_NN x_SYM 36.0_CD 30.3_CD Tax_NNP effect_NN of_IN US_NNP GAAP_NNP adjustments_NNS viii_FW 142.8_CD 55.7_CD Minority_NNP interest_NN xi_FW 75.6_CD Total_JJ US_NNP GAAP_NNP adjustments_NNS 968.2_CD 1,030.7_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 2,140.2_CD 1,627.0_CD Figures_NNS reported_VBN under_IN UK_NNP GAAP_NNP for_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD have_VBP been_VBN restated_VBN following_VBG the_DT introduction_NN of_IN FRS_NNP 19_CD as_IN explained_VBN in_IN note_NN 36_CD ._.
Net_JJ income_NN for_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD and_CC shareholders_NNS equity_NN at_IN 31_CD December_NNP 2001_CD in_IN accordance_NN with_IN US_NNP GAAP_NNP have_VBP been_VBN restated_VBN as_IN outlined_VBN in_IN notes_NNS iv_VBP ,_, vi_FW ,_, viii_NN and_CC ix_NN below_IN ._.
The_DT effect_NN of_IN these_DT restatements_NNS on_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD increases_NNS net_JJ income_NN by_IN 16.1_CD m_NN from_IN 108.3_CD m_NN to_TO 124.4_CD m_NN ,_, with_IN a_DT corresponding_JJ 2.5_CD p_NN increase_NN in_IN basic_JJ net_JJ income_NN per_IN share_NN for_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD ._.
The_DT restatements_NNS have_VBP reduced_VBN shareholders_NNS equity_NN by_IN 1.6_CD m_NN from_IN 1,628.6_CD m_NN to_TO 1,627.0_CD m_NN at_IN 31_CD December_NNP 2001_CD ._.
Amersham_NNP plc_NN 89_CD Supplemental_NNP financial_JJ information_NN continued_VBD i_FW Business_NN combinations_NNS Under_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, acquisitions_NNS are_VBP accounted_VBN for_IN as_IN purchase_NN business_NN combinations_NNS ._.
However_RB ,_, certain_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP in_IN the_DT application_NN of_IN the_DT purchase_NN method_NN of_IN accounting_NN for_IN business_NN combinations_NNS are_VBP set_VBN out_RP below_IN ._.
Goodwill_NNP ,_, intangible_JJ and_CC other_JJ assets_NNS Both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP require_VBP purchase_NN consideration_NN to_TO be_VB allocated_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN at_IN their_PRP$ fair_JJ value_NN on_IN the_DT date_NN of_IN acquisition_NN ,_, with_IN the_DT difference_NN between_IN the_DT consideration_NN and_CC the_DT fair_JJ value_NN of_IN the_DT identiable_JJ net_JJ assets_NNS recorded_VBN as_IN goodwill_NN ._.
Under_IN the_DT requirements_NNS of_IN Financial_NNP Reporting_NNP Standard_NNP FRS_NNP 10_CD Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS ,_, and_CC associates_NNS during_IN accounting_NN periods_NNS ending_VBG on_IN or_CC after_IN 23_CD December_NNP 1998_CD should_MD be_VB capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
This_DT treatment_NN of_IN goodwill_NN is_VBZ similar_JJ to_TO its_PRP$ treatment_NN under_IN US_NNP GAAP_NNP prior_RB to_TO the_DT introduction_NN of_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP 142_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ._.
The_DT impact_NN of_IN the_DT introduction_NN of_IN SFAS_NNP 142_CD is_VBZ discussed_VBN below_IN ._.
However_RB ,_, because_IN FRS_NNP 10_CD need_MD not_RB be_VB applied_VBN retrospectively_RB to_TO goodwill_NN written_VBN off_RP against_IN shareholders_NNS funds_NNS in_IN earlier_JJR years_NNS ,_, there_EX will_MD continue_VB to_TO be_VB differences_NNS between_IN the_DT goodwill_NN calculated_VBN under_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, goodwill_NN written_VBN off_RP against_IN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP has_VBZ been_VBN reinstated_VBN ._.
UK_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN purchase_NN consideration_NN to_TO intangible_JJ assets_NNS ,_, which_WDT are_VBP separable_JJ from_IN the_DT business_NN ._.
For_IN UK_NNP GAAP_NNP purposes_NNS ,_, intangible_JJ assets_NNS ,_, other_JJ than_IN goodwill_NN ,_, acquired_VBN in_IN a_DT business_NN combination_NN ,_, which_WDT are_VBP not_RB separable_JJ and_CC measurable_JJ ,_, are_VBP not_RB capitalized_VBN ._.
US_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN consideration_NN to_TO identiable_JJ intangible_JJ assets_NNS if_IN they_PRP arise_VBP from_IN contractual_JJ or_CC other_JJ legal_JJ rights_NNS :_: if_IN intangible_JJ assets_NNS do_VBP not_RB arise_VB from_IN contractual_JJ or_CC legal_JJ rights_NNS ,_, the_DT asset_NN is_VBZ recognized_VBN apart_RB from_IN goodwill_NN only_RB if_IN it_PRP is_VBZ separable_JJ ._.
The_DT intangible_JJ assets_NNS recognized_VBN for_IN US_NNP GAAP_NNP are_VBP being_VBG amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN periods_NNS up_IN to_TO 10_CD years_NNS ._.
Effect_NN of_IN SFAS_NNP 142_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS Under_IN US_NNP GAAP_NNP ,_, following_VBG the_DT introduction_NN of_IN SFAS_NNP 142_CD ,_, goodwill_NN and_CC intangible_JJ assets_NNS with_IN indefinite_JJ useful_JJ lives_NNS are_VBP not_RB amortised_VBN but_CC reviewed_VBN annually_RB for_IN impairment_NN ._.
The_DT 2002_CD amortisation_NN charge_NN on_IN such_JJ goodwill_NN recognized_VBN for_IN UK_NNP GAAP_NNP has_VBZ been_VBN reversed_VBN for_IN US_NNP GAAP_NNP purposes_NNS ._.
The_DT impact_NN of_IN the_DT introduction_NN of_IN SFAS_NNP 142_CD on_IN net_JJ income_NN and_CC net_JJ income_NN per_IN share_NN is_VBZ analyzed_VBN below_IN :_: 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Restated_VBN m_FW m_FW Net_JJ income_NN Net_JJ income_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP 160.5_CD 124.4_CD Add_VB back_RB :_: Goodwill_NNP amortisation_NN 68.7_CD Adjusted_VBN net_JJ income_NN under_IN US_NNP GAAP_NNP 160.5_CD 193.1_CD Net_JJ income_NN per_IN share_NN basic_JJ p_NN p_NN Net_JJ income_NN per_IN share_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP 23.4_CD 19.6_CD Add_VB back_RB :_: Goodwill_NNP amortisation_NN 10.8_CD Adjusted_VBN net_JJ income_NN per_IN share_NN basic_JJ as_IN reported_VBN under_IN US_NNP GAAP_NNP 23.4_CD 30.4_CD Net_JJ income_NN per_IN share_NN diluted_VBN p_NN p_NN Net_JJ income_NN per_IN share_NN diluted_VBN as_IN reported_VBN under_IN US_NNP GAAP_NNP 23.3_CD 19.5_CD Add_VB back_RB :_: Goodwill_NNP amortisation_NN 10.8_CD Adjusted_VBN net_JJ income_NN per_IN share_NN diluted_VBN as_IN reported_VBN under_IN US_NNP GAAP_NNP 23.3_CD 30.3_CD Purchased_VBN research_NN and_CC development_NN Acquired_VBN in-process_JJ research_NN and_CC development_NN recognized_VBN under_IN US_NNP GAAP_NNP purchase_NN accounting_NN requirements_NNS is_VBZ written_VBN off_RP directly_RB to_TO net_JJ income_NN in_IN the_DT year_NN of_IN acquisition_NN :_: the_DT technological_JJ feasibility_NN of_IN such_JJ in-process_JJ technology_NN not_RB having_VBG been_VBN established_VBN and_CC not_RB having_VBG an_DT alternative_JJ future_JJ use_NN ._.
Acquired_VBN in-process_JJ research_NN and_CC development_NN is_VBZ not_RB recognized_VBN as_IN a_DT separate_JJ asset_NN under_IN UK_NNP GAAP_NNP ._.
Purchase_NN of_IN 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNP Under_IN UK_NNP GAAP_NNP ,_, fair_JJ value_NN adjustments_NNS have_VBP been_VBN recognized_VBN for_IN tangible_JJ xed_JJ assets_NNS ,_, listed_VBN investments_NNS and_CC the_DT funded_JJ status_NN of_IN pensions_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, additional_JJ fair_JJ value_NN adjustments_NNS have_VBP been_VBN recognized_VBN for_IN separable_JJ intangible_JJ assets_NNS ,_, in-process_JJ research_NN and_CC development_NN and_CC the_DT revaluation_NN of_IN inventory_NN ._.
Intangible_JJ assets_NNS are_VBP being_VBG amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN periods_NNS up_IN to_TO 10_CD years_NNS ._.
The_DT in-process_JJ research_NN and_CC development_NN asset_NN has_VBZ been_VBN written_VBN off_RP to_TO income_NN in_IN the_DT year_NN ._.
Following_VBG the_DT introduction_NN of_IN SFAS_NNP 142_CD ,_, goodwill_NN amortisation_NN recorded_VBN under_IN UK_NNP GAAP_NNP has_VBZ been_VBN reversed_VBN for_IN US_NNP GAAP_NNP purposes_NNS ._.
Investment_NN in_IN Nycomed_NNP Pharma_NNP The_NNP 29_CD %_NN investment_NN in_IN Nycomed_NNP Pharma_NNP was_VBD recorded_VBN under_IN the_DT cost_NN method_NN of_IN accounting_NN under_IN UK_NNP GAAP_NNP prior_RB to_TO its_PRP$ disposal_NN as_IN the_DT company_NN did_VBD not_RB exert_VB significant_JJ inuence_NN over_IN the_DT entity_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT investment_NN was_VBD accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
ii_FW Accounting_NN for_IN investment_NN in_IN Nihon_NNP Medi-Physics_NNP NMP_NNP Under_IN UK_NNP GAAP_NNP the_DT change_NN from_IN the_DT cost_NN method_NN to_TO the_DT equity_NN method_NN in_IN the_DT year_NN ended_VBD 31_CD March_NNP 1997_CD ,_, due_JJ to_TO the_DT acquisition_NN of_IN an_DT additional_JJ interest_NN in_IN NMP_NNP ,_, did_VBD not_RB require_VB retroactive_JJ adjustment_NN to_TO the_DT financial_JJ statements_NNS ._.
Under_IN US_NNP GAAP_NNP the_DT investment_NN ,_, the_DT results_NNS of_IN operations_NNS ,_, and_CC shareholders_NNS equity_NN of_IN the_DT group_NN were_VBD adjusted_VBN retroactively_RB in_IN a_DT manner_NN consistent_JJ with_IN the_DT accounting_NN for_IN a_DT step-by-step_JJ acquisition_NN of_IN a_DT subsidiary_NN ._.
90_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD iii_FW Disposal_NNP of_IN Nycomed_NNP Pharma_NNP In_IN 2001_CD ,_, the_DT group_NN sold_VBD its_PRP$ trade_NN investment_NN in_IN Nycomed_NNP Pharma_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT investment_NN was_VBD treated_VBN as_IN an_DT associate_JJ company_NN resulting_VBG in_IN a_DT lower_JJR profit_NN on_IN disposal_NN under_IN the_DT equity_NN method_NN of_IN accounting_NN ._.
Certain_JJ costs_NNS associated_VBN with_IN the_DT sale_NN have_VBP been_VBN recognized_VBN in_IN 2002_CD for_IN US_NNP GAAP_NNP ._.
iv_NN Derivative_JJ hedging_NN Under_IN US_NNP GAAP_NNP ,_, the_DT group_NN does_VBZ not_RB qualify_VB for_IN hedge_JJ accounting_NN and_CC so_RB gains_NNS and_CC losses_NNS arising_VBG on_IN derivative_JJ instruments_NNS at_IN the_DT year_NN end_NN have_VBP been_VBN booked_VBN directly_RB to_TO income_NN under_IN US_NNP GAAP_NNP ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT group_NN determined_VBD that_IN the_DT adjustment_NN relating_VBG to_TO gains_NNS and_CC losses_NNS arising_VBG on_IN derivative_JJ instruments_NNS for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2001_CD had_VBD been_VBN incorrectly_RB accounted_VBN for_IN under_IN SFAS_NNP 133_CD Accounting_NN for_IN derivative_JJ instruments_NNS and_CC hedging_VBG activities_NNS ._.
Accordingly_RB ,_, the_DT group_NN has_VBZ restated_VBN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD ._.
The_DT adjustment_NN to_TO net_JJ income_NN in_IN 2001_CD has_VBZ correspondingly_RB increased_VBN by_IN 21.0_CD m_NN to_TO 5.6_CD m_NN and_CC the_DT adjustment_NN to_TO shareholders_NNS equity_NN has_VBZ increased_VBN by_IN 3.2_CD m_NN to_TO 12.8_CD m_NN at_IN 31_CD December_NNP 2001_CD ._.
v_NN Pensions_NNS and_CC post_NN retirement_NN costs_NNS Under_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, pension_NN and_CC post_NN retirement_NN costs_NNS are_VBP based_VBN on_IN actuarial_JJ assumptions_NNS ._.
However_RB ,_, under_IN UK_NNP GAAP_NNP the_DT cost_NN is_VBZ based_VBN on_IN long_JJ term_NN market_NN and_CC economic_JJ assumptions_NNS and_CC under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ based_VBN on_IN current_JJ market_NN and_CC economic_JJ assumptions_NNS ._.
In_IN line_NN with_IN SFAS_NNP 87_CD Employers_NNS accounting_VBG for_IN pensions_NNS an_DT additional_JJ minimum_NN liability_NN equal_JJ to_TO the_DT unfunded_JJ accumulated_VBN benefit_NN obligation_NN is_VBZ recognized_VBN when_WRB the_DT accumulated_VBN benefit_NN obligation_NN exceeds_VBZ the_DT fair_JJ value_NN of_IN pension_NN fund_NN assets_NNS ._.
vi_FW Transfer_NN of_IN assets_NNS from_IN pension_NN plans_NNS A_DT transfer_NN of_IN assets_NNS was_VBD received_VBN from_IN former_JJ pension_NN plans_NNS during_IN 2001_CD ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT proportion_NN of_IN the_DT transfer_NN relating_VBG to_TO current_JJ employees_NNS of_IN the_DT group_NN is_VBZ being_VBG spread_VBN over_IN the_DT remaining_VBG service_NN life_NN of_IN the_DT employees_NNS in_IN line_NN with_IN SSAP_NNP 24_CD ._.
Under_IN US_NNP GAAP_NNP ,_, this_DT was_VBD taken_VBN to_TO income_NN in_IN 2001_CD ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT group_NN determined_VBD that_IN income_NN recognized_VBN in_IN the_DT year_NN ending_VBG 31_CD December_NNP 2001_CD relating_VBG to_TO the_DT transfer_NN of_IN assets_NNS from_IN former_JJ pension_NN plans_NNS had_VBD been_VBN incorrectly_RB accounted_VBN for_IN under_IN US_NNP GAAP_NNP ._.
Net_JJ income_NN in_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD has_VBZ been_VBN restated_VBN and_CC income_NN recognized_VBN on_IN the_DT transfer_NN of_IN assets_NNS reduced_VBN by_IN 1.0_CD m_NN to_TO 6.0_CD m._FW The_DT adjustments_NNS to_TO shareholders_NNS equity_NN at_IN 31_CD December_NNP 2001_CD has_VBZ also_RB been_VBN restated_VBN ,_, with_IN a_DT corresponding_JJ reduction_NN of_IN 1.0_CD m_NN to_TO 6.0_CD m._FW vii_FW Revenue_NN recognition_NN Under_IN UK_NNP GAAP_NNP ,_, contract_NN revenue_NN is_VBZ recognized_VBN when_WRB it_PRP is_VBZ earned_VBN and_CC non-refundable_JJ and_CC when_WRB there_EX are_VBP no_DT future_JJ obligations_NNS under_IN the_DT contract_NN terms_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT group_NN applies_VBZ Staff_NNP Accounting_NNP Bulletin_NNP 101_CD SAB_NNP 101_CD ._.
Under_IN SAB_NNP 101_CD ,_, more_JJR prescriptive_JJ criteria_NNS are_VBP applied_VBN to_TO assess_VB whether_IN the_DT culmination_NN of_IN the_DT earnings_NNS process_NN has_VBZ occurred_VBN and_CC the_DT group_NN has_VBZ a_DT continuing_VBG obligation_NN throughout_IN the_DT contract_NN terms_NNS ._.
As_IN a_DT result_NN ,_, certain_JJ non-refundable_JJ fees_NNS have_VBP been_VBN deferred_VBN over_IN the_DT contract_NN terms_NNS under_IN US_NNP GAAP_NNP ._.
viii_FW Deferred_JJ taxation_NN Under_IN UK_NNP GAAP_NNP ,_, provision_NN for_IN deferred_VBN taxation_NN is_VBZ recorded_VBN under_IN FRS_NNP 19_CD ._.
Except_IN for_IN certain_JJ timing_NN differences_NNS relating_VBG to_TO revaluations_NNS ,_, rolled_VBD over_IN taxable_JJ gains_NNS and_CC unremitted_JJ income_NN ,_, provision_NN is_VBZ made_VBN for_IN all_DT timing_NN differences_NNS that_WDT would_MD give_VB rise_VB to_TO a_DT deferred_VBN tax_NN liability_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB they_PRP will_MD be_VB recoverable_JJ ._.
Under_IN US_NNP GAAP_NNP ,_, deferred_VBN tax_NN is_VBZ provided_VBN for_IN on_IN a_DT full_JJ liability_NN basis_NN ._.
A_DT valuation_NN allowance_NN is_VBZ established_VBN when_WRB it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN asset_NN will_MD not_RB be_VB realized_VBN ._.
Following_VBG the_DT adjustments_NNS to_TO net_JJ income_NN in_IN the_DT 12_CD months_NNS to_TO 31_CD December_NNP 2001_CD ,_, as_IN outlined_VBN in_IN notes_NNS iv_VBP and_CC vi_VBP ,_, the_DT tax_NN effects_NNS of_IN the_DT US_NNP GAAP_NNP adjustments_NNS have_VBP been_VBN reduced_VBN by_IN 3.9_CD m_NN to_TO 20.5_CD m._FW The_DT adjustment_NN to_TO shareholders_NNS equity_NN at_IN 31_CD December_NNP 2001_CD has_VBZ been_VBN correspondingly_RB reduced_VBN by_IN 0.7_CD m_NN to_TO 55.7_CD m._FW ix_FW Other_JJ Other_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP relate_VBP to_TO accounting_VBG for_IN compensated_VBN absences_NNS ,_, investments_NNS in_IN equity_NN securities_NNS ,_, ESOP_NNP transactions_NNS and_CC stock_NN based_VBN compensation_NN ._.
Certain_JJ balances_NNS have_VBP been_VBN reclassied_VBN in_IN 2001_CD from_IN Business_NNP combinations_NNS to_TO Other_JJ to_TO conform_VB to_TO current_JJ year_NN presentation_NN ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT group_NN determined_VBD that_IN the_DT adjustment_NN to_TO shareholders_NNS equity_NN at_IN 31_CD December_NNP 2001_CD relating_VBG to_TO ESOP_NNP transactions_NNS had_VBD been_VBN incorrectly_RB calculated_VBN ._.
Correspondingly_RB ,_, the_DT adjustment_NN to_TO shareholders_NNS equity_NN at_IN 31_CD December_NNP 2001_CD has_VBZ been_VBN restated_VBN with_IN a_DT reduction_NN of_IN 3.1_CD m_NN to_TO 23.7_CD m._FW x_SYM Ordinary_NNP dividends_NNS Under_IN UK_NNP GAAP_NNP ,_, dividends_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT period_NN in_IN respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN the_DT Board_NNP of_IN Directors_NNS for_IN approval_NN by_IN the_DT shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, dividends_NNS are_VBP recorded_VBN as_IN a_DT reduction_NN to_TO retained_VBN earnings_NNS when_WRB they_PRP have_VBP been_VBN formally_RB declared_VBN ,_, and_CC notice_VB given_VBN to_TO shareholders_NNS ._.
xi_FW Minority_NNP interest_NN The_DT amount_NN represents_VBZ the_DT components_NNS of_IN the_DT US_NNP GAAP_NNP adjustments_NNS attributable_JJ to_TO Pharmacia_NNP Corporations_NNS 45_CD %_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS ._.
The_DT minority_NN interest_NN was_VBD extinguished_VBN in_IN 2002_CD on_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS that_IN the_DT group_NN did_VBD not_RB already_RB own_VB ._.
